VTRS
ViatrisNASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-05-08
As of May 8, 2026, VTRS has a composite score of 15.2 and a signal label of "mild favorable." The company momentum score increased by 16.9 points to 36.3, contributing positively to the overall assessment. However, the outlook includes unfavorable scenarios, such as potential guidance cuts and labor state reversals, which could impact future estimates. This analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share0.01
- Slope (norm)-0.81
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $0.60 → $0.61 (+1.0% / 30d). 1 raised, 1 cut, 8 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 55% of analysts rate Buy.
1 PT revisions / 30d. Avg target 18.0% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
6 material events in the last 24 months — top 5 listed below.
Stated priorities
2 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Enterprise-wide strategic review (EWSR)costbehind0% progress
2/26: “Viatris initiated an EWSR to enable the Company to build a more focused, efficient and future-ready organization.”
Why this status
Stated in 2 of last 2 quarters. The EWSR aims to create a more efficient organization. However, financials show a net income decline from $113.9M in 2025-Q1 to -$615.3M in 2025-Q4, indicating limited progress so far.
- 2.Reaffirm 2026 financial guidancegrowthmixed35% progress
5/7: “Viatris is reaffirming its 2026 financial guidance ranges, as set forth below.”
Why this status
Stated in 2 of last 2 quarters. Viatris reaffirmed its 2026 revenue guidance of $14,450M to $14,950M. However, revenue declined from $3,759.9M in 2025-Q3 to $3,733.9M in 2025-Q4, indicating challenges in meeting guidance.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 36%; 252d 33%.
Drawdown — Max 1y −19%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.88 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 46/100, drawdown 62/100, beta 88/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- score change · company_momentum_scoreseverity 28
Company momentum rose by 16.9 points (from 19.4 to 36.3).
As of May 8, 2026, the company momentum score for VTRS rose by 16.9 points, increasing from 19.4 to 36.3. The overall signal transitioned to "mild favorable." However, the forward view indicates an unfavorable scenario if next-quarter guidance is cut, which is currently reaffirmed as of May 7, 2026. Additionally, there are unfavorable scenarios related to labor state reversal and sector trend weakening.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Enterprise-wide strategic review (EWSR)
CostImplement restructuring activities as part of the EWSR to build a more focused and efficient organization.
BehindStated in 2 of last 2 quarters. The EWSR aims to create a more efficient organization. However, financials show a net income decline from $113.9M in 2025-Q1 to -$615.3M in 2025-Q4, indicating limited progress so far.
0%CEO/CFO:“Viatris initiated an EWSR to enable the Company to build a more focused, efficient and future-ready organization.”Multiple sourcesSource dated 2026-02-26Stated 2 of last 8 quartersFirst seen 2026-02-26Show history (2)
- 2026-Q1Multiple sources
“Viatris initiated an EWSR to enable the Company to build a more focused, efficient and future-ready organization.”
- 2025-Q4Multiple sources
“Viatris initiated an enterprise-wide strategic review to build a more focused organization.”
- #2
Reaffirm 2026 financial guidance
GrowthNew since 2026-05-07Maintain the 2026 financial guidance ranges for revenue, FCF, and EPS.
MixedStated in 2 of last 2 quarters. Viatris reaffirmed its 2026 revenue guidance of $14,450M to $14,950M. However, revenue declined from $3,759.9M in 2025-Q3 to $3,733.9M in 2025-Q4, indicating challenges in meeting guidance.
35%CEO/CFO:“Viatris is reaffirming its 2026 financial guidance ranges, as set forth below.”Multiple sourcesSource dated 2026-05-07Stated 2 of last 8 quartersFirst seen 2026-05-07Show history (2)
- 2026-Q1Multiple sources
“Viatris is reaffirming its 2026 financial guidance ranges, as set forth below.”
- 2025-Q4Multiple sources
“The Company is providing the following financial guidance metrics for fiscal year 2026.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
P/E over the last 5 years
9 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
VTRS Viatris | +15 | inexpensive | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently REAFFIRMED as of 2026-05-07)+4.0 pts
- If next-quarter guidance is cut (currently REAFFIRMED as of 2026-05-07)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-044d agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity. Ms. Mistras will cease to serve as Chief Financial Officer effective May 8, 2026 and will remain employed by the Company until May 22, 2026 for transition…
executive changeneutralscore 73 - 2026-05-071d agoItem 2.02
Results of Operations and Financial Condition. On May 7, 2026 , Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…
earnings preannouncement—score 64 - 2026-02-262mo agoItem 2.02
Results of Operations and Financial Condition. On February 26, 2026, Viatris Inc. (“Viatris” or the “Company”) issued a press release reporting the Company's financial results for the period ended December 31, 2025 and announcing 2026 guidance. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange A…
earnings preannouncementneutralscore 13 - 2026-02-262mo agoItem 2.05
Costs Associated with Exit or Disposal Activities. In 2025, Viatris initiated an enterprise-wide strategic review (“EWSR”) to enable the Company to build a more focused, efficient and future-ready organization and position the Company for sustained growth beginning in 2026. On February 26, 2026, the Company announced the results of its EWSR, and as a part of the review, committed to and began implementation of certain restructuring activities. These restructuring activities are expected to op…
product or strategy shiftnegativescore 12 - 2026-02-262mo agoItem 8.01
Other Events. As previously announced, Viatris will host a conference call and live webcast today at 8:30 a.m. ET to review the Company's financial results for the fourth quarter and full year 2025. Forward-Looking Statements. This report includes statements that constitute “forward-looking statements” regarding the expected financial performance of Viatris and its strategic and operational plans, including statements regarding Viatris initiated an EWSR to enable the Company to build a more f…
product or strategy shiftnegativescore 10
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.